Abstract Submission

Late breaking abstract submission was open until 15 August 2021.
Please contact us via [email protected] for further questions.

Format information:

Maximum Number of Words
2,500 characters (including spaces)

Tables/Pictures
No tables are allowed.
No pictures are allowed.

Authors
Authors and institution must be named, the presenter (or presenting author) must be underlined.

Presenting authors should register upon submitting their abstract. Registration must be completed at the latest upon confirmation that the abstract has been accepted as an oral or poster presentation.

Deadline
15 August 2021

Contact
Please contact the EMAS 2021 Secretariat at: [email protected] for all abstract enquiries.

Notification of acceptance
All late breaking abstracts will be peer reviewed and authors notified end of August 2021 whether or not their abstract has been accepted as an oral or a poster presentation.

 

Abstract Publication

The accepted regular abstracts will be published on this website and also in the October 2021 issue of Maturitas, the official EMAS journal.

Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond. https://www.maturitas.org

The Scientific Committee invites worldwide experts to submit their abstracts for review and possibly present on the following topics:

1. Menopause and climacteric

1.1. Climacteric symptoms

1.2. Complementary and alternative medicine

1.3. Diet, lifestyle and dietary supplements

1.4. Female sexual dysfunction

1.5. Menopausal hormone therapy, and non-hormone therapy

1.6. Menopause in the workplace

1.7. Osteoporosis

1.8. Ovarian ageing

1.9. Perimenopause

1.10. Premature menopause

1.11. Quality of life

1.12. Urogenital ageing

 

2. Gynaecology and women’s health

2.1. Assisted reproduction

2.2. Benign breast disease

2.3. Benign gynaecology

2.4. Breast cancer

2.5. Contraception and fertility

2.6. Endocrine disrupters

2.7. Endocrinology

2.8. Gynaecological cancer

2.9. Hormone and Non-hormone therapy

2.10. Sexual orientation and gender identity

2.11. Sexual health

2.12. Urogynaecology

 

3. Andropause and men’s health

3.1.Androgens and androgen receptor modulators

3.2. Cancer

3.3. Complementary and alternative therapies

3.4. Endocrinology

3.5. Male sexual dysfunction

3.6. Urinary incontinence

4. Midlife health and ageing

4.1. Cardiovascular disease

4.2. Complementary and alternative therapies

4.3. Cross-cultural differences

4.4. Degenerative disorders

4.5. Dementia and cognition

4.6. Depression and anxiety

4.7. Diet and lifestyle

4.8. Dietary supplements

4.9. Endocrinology of aging

4.10. Epidemiology

4.11. Frailty

4.12. Gender differences in chronic disease

4.13. Health and social care

4.14. Metabolic disorders

4.15. Midlife health and aging

4.16. Neurological disease

4.17. Obesity

4.18. Occupational medicine

4.19. Osteoporosis and arthritis

4.20. Predictors of disease in later life

4.21. Sarcopenia

4.22. Screening

4.23. Skin ageing

4.24. Sleep

 

5. Innovation

5.1. Artificial Intelligence, Digital Age and Machine Learning

5.2. Basic science

5.3. COVID-19

5.4. Diagnostics

5.5. Drug discovery

5.6. Information and Communication Technology

5.7. Telemedicine and virtual reality

5.8. Surgery